XENE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.203

+43.23%

-1.130

+36.14%

-1.186

+10.81%

Estimates Revision

The market is revising No Change the revenue expectations for Xenon Pharmaceuticals Inc. (XENE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 22.24%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+22.24%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.59 USD with a low forecast of 44.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

0 Hold

0 Sell

Strong Buy

Current: 43.590

Low

44.00

Averages

55.59

High

65.00

Current: 43.590

Low

44.00

Averages

55.59

High

65.00

JPMorgan

NULL -> Overweight

maintain

$57 -> $60

2025-11-18

Reason

JPMorgan

Price Target

$57 -> $60

2025-11-18

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Xenon Pharmaceuticals to $60 from $57 and keeps an Overweight rating on the shares. The firm updated the company's model.

RBC Capital

Outperform

maintain

$55 -> $58

2025-11-04

Reason

RBC Capital

Price Target

$55 -> $58

2025-11-04

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $58 from $55 and keeps an Outperform rating on the shares. The timelines for X-TOLE2 remain intact for early 2026, and the firm continues to see a high chance of success at 75% based on prior azetukalner phase 2b and OLE data, the analyst tells investors in a research note.

Wells Fargo

Benjamin Burnett

Overweight

downgrade

$48 -> $44

2025-11-04

Reason

Wells Fargo

Benjamin Burnett

Price Target

$48 -> $44

2025-11-04

downgrade

Overweight

Reason

Wells Fargo analyst Benjamin Burnett lowered the firm's price target on Xenon Pharmaceuticals to $44 from $48 and keeps an Overweight rating on the shares. The firm thinks the X-TOLE2 study is likely to work as it's designed after a highly positive Phase 2 study. That said, Wells thinks "bogey" for median seizure reduction is being debated, and call commentary about this could drive some weakness in shares.

Wells Fargo

Overweight

initiated

$48

2025-09-02

Reason

Wells Fargo

Price Target

$48

2025-09-02

initiated

Overweight

Reason

Wells Fargo assumed coverage of Xenon Pharmaceuticals with an Overweight rating and $48 price target. The company expects the readout of its Phase 3 X-TOLE2 study involving lead asset, azetukalner, in Focal Onset Seizures in early 2026, and the firm believes that azetukalner is likely to succeed in X-TOLE2 given the strong Phase 2 data, the analyst tells investors in a research note. The 10mg dose worked in Phase 2, implying some room for efficacy pullback in Phase 3, the firm added.

RBC Capital

Brian Abrahams

Outperform

downgrade

$57 -> $55

2025-08-12

Reason

RBC Capital

Brian Abrahams

Price Target

$57 -> $55

2025-08-12

downgrade

Outperform

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Xenon Pharmaceuticals to $55 from $57 but keeps an Outperform rating on the shares after its Q2 results. The enrollment completion for X-TOLE2 pivotal along with intact timeline for early-FY26 top-line readout is likely to reassure investors, the analyst tells investors in a research note. RBC adds that it continues to have high confidence based on prior azetukalner phase 2 and OLE data, as well as historical phase 2 to phase 3 translatability in FOS, that the Kv7 will recapitulate its compelling efficacy and safety profile and unlock a $1.2B long-term opportunity.

Wells Fargo

Mohit Bansal

Overweight

maintain

$50 -> $47

2025-05-13

Reason

Wells Fargo

Mohit Bansal

Price Target

$50 -> $47

2025-05-13

maintain

Overweight

Reason

Wells Fargo analyst Mohit Bansal lowered the firm's price target on Xenon Pharmaceuticals to $47 from $50 and keeps an Overweight rating on the shares. After enrollment completion was pushed back from the second half of 2024 and now top-line data pushed to early 2026, the firm can see investor concerns around X-TOLE2 program and lack of catalyst this year. Though not statistical significant, Mt. Sinai data was reassuring for MDD activity, Wells adds.

Valuation Metrics

The current forward P/E ratio for Xenon Pharmaceuticals Inc (XENE.O) is -9.22, compared to its 5-year average forward P/E of -12.06. For a more detailed relative valuation and DCF analysis to assess Xenon Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.06

Current PE

-9.22

Overvalued PE

-9.50

Undervalued PE

-14.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-3.31

Undervalued EV/EBITDA

-11.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2107.64

Current PS

0.00

Overvalued PS

5744.91

Undervalued PS

-1529.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 26068.42% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 26068.42% over the last month.

Sold

Bought

XENE News & Events

Events Timeline

No data

News

8.0

12-08NASDAQ.COM

Significant Monday Options Trading: MDB, XENE, SNOW

3.5

12-05Globenewswire

Xenon Pharmaceuticals Reports 90.9% Monthly Seizure Frequency Reduction in Long-Term Azetukalner Study

3.5

12-05Newsfilter

Xenon Reports 90.9% Seizure Frequency Reduction in Long-Term Epilepsy Study

People Also Watch

Frequently Asked Questions

What is Xenon Pharmaceuticals Inc (XENE) stock price today?

The current price of XENE is 43.59 USD — it has decreased -0.02 % in the last trading day.

What is Xenon Pharmaceuticals Inc (XENE)'s business?

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

What is the price predicton of XENE Stock?

What is Xenon Pharmaceuticals Inc (XENE)'s revenue for the last quarter?

Xenon Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Xenon Pharmaceuticals Inc (XENE)'s earnings per share (EPS) for the last quarter?

Xenon Pharmaceuticals Inc. EPS for the last quarter amounts to -1.15 USD, increased 41.98 % YoY.

What changes have occurred in the market's expectations for Xenon Pharmaceuticals Inc (XENE)'s fundamentals?

How many employees does Xenon Pharmaceuticals Inc (XENE). have?

Xenon Pharmaceuticals Inc (XENE) has 316 emplpoyees as of December 16 2025.

What is Xenon Pharmaceuticals Inc (XENE) market cap?

Today XENE has the market capitalization of 3.37B USD.